The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Researchers have understood for decades the importance that DNA repair mechanisms play in maintaining genomic integrity and keeping carcinogenesis in check. For instance, the BRACA1/2 genes and ...

Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...

Investigators evaluated the association between risk-reducing bilateral mastectomy and overall and breast cancer–specific mortality in female carriers of BRCA pathogenic variants.

In May 2013, nearly 20 years after the discovery that mutations on the BRCA1 and BRCA2 genes could lead to a higher risk of breast and ovarian cancer, A-list Hollywood actress Angelina Jolie garnered ...

Pathway Genomics said that it has launched BRCATrue, a next- generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian ...

Since the NHS Jewish BRCA Testing Programme began in January 2023, around 11,000 saliva tests have been processed, with 235 people (2.1%) testing positive for a BRCA gene mutation, according to new ...

Among the 124 undergoing germline testing based on high risk, their average age was 56 (range 34–77). Again, germline BRCA2 variation predominated, with 8 (8%) testing positive, but only one (less ...